News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Hoitt Jason
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/14/2023 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Provention Bio, Inc.|
Txns:
| Sold 4,500 shares
@ $10.0012, valued at
$45k
|
|
| 01/11/2023 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Provention Bio, Inc.|
Txns:
| Granted 200,000 options to buy
@ $8.93, valued at
$1.8M
|
|
| 12/09/2022 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Provention Bio, Inc.|
Txns:
| Granted 120,000 options to buy
@ $14.97, valued at
$1.8M
Granted 20,663 options to buy
@ $12.62, valued at
$260.8k
|
|
| 01/20/2022 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Provention Bio, Inc.|
Txns:
| Granted 145,000 options to buy
@ $4.39, valued at
$636.6k
|
|
| 05/14/2021 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Provention Bio, Inc.|
Txns:
| Granted 139,500 options to buy
@ $6.8, valued at
$948.6k
|
|
| 07/16/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/08/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/16/2019 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Sold 6,680 shares
@ $15.1, valued at
$100.9k
Sold 900 shares
@ $16.44, valued at
$14.8k
|
|
| 07/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/10/2019 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Sold 2,387 shares
@ $8.77, valued at
$20.9k
|
|
| 12/20/2018 |
4
| Hoitt Jason (Chief Commercial Officer) has filed a Form 4 on Dova Pharmaceuticals Inc.|
Txns:
| Granted 24,711 shares
@ $0
Granted 250,000 options to buy
@ $6.07, valued at
$1.5M
|
|
|
|